Entopsis

Entopsis

Funded by Breakout Labs May 2012
in Miami, FL

Entopsis is using nanoengineering to develop an inexpensive, label-free, universal diagnostic platform that simultaneously evaluates small molecules, proteins and cells from any sample in less than one hour. Rather than relying on predetermined biological molecules like nucleotides, antibodies or peptides to identify specific markers, the company is developing a synthetic biomarker capture device based on systematic alterations to biocompatible materials. Resulting binding signatures provide diagnostic and prognostic metrics that guide clinical decisions. Co-founders Obdulio Piloto and Ian Cheong first met more than 10 years ago during their graduate work on cancer therapeutics at the Johns Hopkins University School of Medicine. Their goal is to revolutionize how diseases are identified, monitored and treated while decreasing health care costs and improving patient outcomes. Breakout Labs funding has enabled them to develop an optimized process for manufacturing their novel device prototype, and to demonstrate successful platform implementation to accurately detect various cancers from patient samples. Their next step is to refine the prototype into a commercially viable platform for both research and clinical implementation.